Prunetin

Prunetin

SCHEMBL73420

COc1cc(O)c2c(=O)c(-c3ccc(O)cc3)coc2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH2 P05091 1/20 1.00
NPC1 O15118 7/20 0.90
RAB9A P51151 7/20 0.90
SMN1; SMN2 Q16637 7/20 0.90
MEN1 O00255 6/20 0.90
KMT2A Q03164 6/20 0.90
CYP2C9 P11712 4/20 0.90
CYP2C19 P33261 4/20 0.90
NFKB1 P19838 3/20 0.90
NFKB2 Q00653 3/20 0.90
RELA Q04206 3/20 0.90
CYP2D6 P10635 3/20 0.90
CYP1A2 P05177 2/20 0.90
TP53 P04637 6/20 0.79
MAPT P10636 6/20 0.79
HPGD P15428 6/20 0.79
ALDH1A1 P00352 6/20 0.79
CYP3A4 P08684 6/20 0.79
KDM4E B2RXH2 5/20 0.79
HSD17B10 Q99714 5/20 0.79

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Prunetin SCHEMBL29612430 1.00 ALDH2 (1.00) ALDH2NPC1RAB9ASMN1; SMN2MEN1
4',7-Dimethoxy-5-Hydroxygenistein SCHEMBL572108 0.95 RAB9A (1.00) ALDH2NPC1RAB9ASMN1; SMN2MEN1
5-Hydroxy-7-Methoxyisoflavone SCHEMBL6142401 0.91 RAB9A (0.83) ALDH2NPC1RAB9ASMN1; SMN2MEN1
SCHEMBL28788159 0.90 KDM4E (0.83) ALDH2NPC1RAB9ASMN1; SMN2MEN1
SCHEMBL16226987 0.90 ALDH2 (0.81) ALDH2NPC1RAB9ASMN1; SMN2MEN1
SCHEMBL2313317 0.90 NPC1 (0.81) ALDH2NPC1RAB9ASMN1; SMN2MEN1
Biochanin SCHEMBL29410271 0.88 RAB9A (1.00) ALDH2NPC1RAB9ASMN1; SMN2MEN1
Biochanin SCHEMBL61258 0.88 RAB9A (1.00) ALDH2NPC1RAB9ASMN1; SMN2MEN1
Genistein SCHEMBL18241115 0.88 MEN1 (0.89) ALDH2NPC1RAB9ASMN1; SMN2MEN1
SCHEMBL2751306 0.87 NPC1 (0.77) ALDH2NPC1RAB9ASMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1378 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-121276055-B Function and application of lysine deficiency type protein kinase 2 inhibitor in inhibiting ventricular remodeling 温州医科大学附属第一医院 2026-05-19 CN claimed
EP-2603098-B1 METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER FIRMENICH INCORPORATED (US) 2025-08-06 EP claimed
CN-120131496-A Composition for improving skin problems caused by unbalanced skin homeostasis and preparation method thereof 中央民族大学 2025-06-13 CN claimed
CN-119925454-A Application of cajan leaf in rats with chronic myelosuppression caused by MTX 浙江中医药大学 2025-05-06 CN claimed
CN-119780447-A Biomarker for early pregnancy related state of dairy cows and application thereof 宁夏大学 2025-04-08 CN claimed
US-20250051551-A1 IMPROVED POLYMER COMPOSITES WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) 2025-02-13 US claimed
CN-118831107-A Ural licorice extract and preparation method and application thereof 成都大学 2024-10-25 CN claimed
US-20240315965-A1 COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS Natural Extraction Systems, LLC (US) 2024-09-26 US claimed
US-20240042396-A1 Polymeric Membrane SOLVENTUM INTELLECTUAL PROPERTIES COMPANY 2024-02-08 US claimed
CN-117298006-A Nanoparticle as well as preparation method and application thereof 上海澄穆实业发展有限公司 2023-12-29 CN claimed
WO-2002100478-A9 ACCELERATORS FOR INCREASING THE RATE OF FORMATION OF FREE RADICALS AND REACTIVE OXYGEN SPECIES CAVALIER DISCOVERY (US) 2003-03-27 WO claimed
WO-2002100478-A2 ACCELERATORS FOR INCREASING THE RATE OF FORMATION OF FREE RADICALS AND REACTIVE OXYGEN SPECIES CAVALIER DISCOVERY (US) 2002-12-19 WO claimed
WO-2002087517-A2 USE OF ISOFLAVONOIDS IN COSMETIC OR DERMATOLOGICAL PREPARATIONS FOR THE PROPHYLAXIS OR TREATMENT OF SENSITIVE SKIN BEIERSDORF AG (DE) 2002-11-07 WO claimed
US-20020107282-A1 Cosmetic composition containing an aminophenol derivative and an isoflavonoid L'OREAL (FR) 2002-08-08 US claimed
CN-1352935-A Cosmetics composition containing aminophenol derivatives and isoflavone like substance OREAL (FR) 2002-06-12 CN claimed
US-6329422-B1 ENHANCING, STIMULATING CHLORIDE TRANSPORT IN EPITHELIAL CELLS; FLAVONE OR ISOFLAVONE OR A STEREOISOMER THEREOF. CHILDREN'S HOSPITAL OAKLAND RESEARCH INSTITUTE 2001-12-11 US claimed
EP-1024803-A1 FLAVONOIDS FOR CYSTIC FIBROSIS THERAPY Children's Hospital Medical Center of Northern California (US) 2000-08-09 EP claimed
US-5958946-A APPLYING GLUCURONIC ACID GILLETTE COMPANY, THE (A DELAWARE CORPORATION) 1999-09-28 US claimed
WO-1999018953-A1 FLAVONOIDS FOR CYSTIC FIBROSIS THERAPY CHILDREN'S HOSPITAL MEDICAL CENTER OF NORTHERN CALIFORNIA (US) 1999-04-22 WO claimed
WO-1998021946-A1 COMPOSITION AND TREATMENT FOR PERSISTENT REPRODUCTIVE TRANSITION SYMPTOMS INTERNUTRIA, INC. (US) 1998-05-28 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107282-A1 Cosmetic composition containing an aminophenol derivative and an isoflavonoid TYR, CYP19A1, EYA3 ALDH2 2429/4885NPC1 4489/4885RAB9A 3324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.